Skip to main content

Table 1 Patient characteristics

From: The effect of clopidogrel on platelet activity in patients with and without type-2 diabetes mellitus: a comparative study

 

Control

Diabetes

(n = 32)

(n = 32)

Age (y)

64.8 ± 12.5

70.2 ± 8.2

Sex (% women)

21.9

21.9

Platelets (nl)

248.5 ± 89.4

223.0 ± 75.4

BMI (kg/m2)

25.5 ± 3.2

30.0 ± 5.4

Leucocytes (nl)

6.9 ± 1.8

7.5 ± 2.5

HbA1c (%)

5.6 ± 0.3

7.2 ± 1.2

Fasting blood glucose (mg/dl)

84 ± 16.0

151 ± 33.1

CRP (mg/dl)

0.6 ± 1.5

0.8 ± 1.7

Cholesterol (mg/dl)

160 ± 33.5

157 ± 39.3

Triglycerides (mg/dl)

150 ± 69.9

165 ± 51.2

HDL-cholesterol (mg/dl)

45.8 ± 11.3

46.8 ± 18.9

LDL-cholesterol (mg/dl)

95.1 ± 24.1

98.2 ± 28.8

Concomitant drugs

  

   Statin (%)

96.9

100

   CCB (%)

90.1

65.6

ASA-100 mg/d (%)

100

100

Antidiabetic drugs

  

   Metformin (%)

0

59.4

   Insulin (%)

0

31.3

   Other/none (%)

0

25.0

Clopidogrel

  

  Loading dose-300 mg (%)

43.8

40.6

  Maintenance dose-75 mg/d (%)

100

100

  1. Legend: BMI, body mass index; HbA1c, glycated hemoglobin; CRP, C-reactive protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein; CCB, calcium channel blocker; ASA, acetylsalicylic acid.